ClinicalTrials.gg
CompletedNCT04138238Updated Jul 12, 2023

Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent

An observational study in Coronary Artery Disease, sponsored by Sahajanand Medical Technologies Limited. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Sahajanand Medical Technologies Limited · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Enrollment
38th of 117
1,200 · median 550
Started
2020
with 18 others
Observational
117 of 365
22 open now
Registered
284th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 38th largest by enrollment of the 117 observational ones that give a count, is one of 19 that started in 2020, is one of 117 observational ones, and was the 284th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex arm of the TALENT trial) and demonstrate that the Supraflex Cruz stent is not inferior to the BioFreedom stent in High Bleeding Risk (HBR) patients (400 patients) with respect to device oriented composite endpoint (DOCE) at 12 months. All patients will be followed up to 12 months after the index procedure.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Supraflex Cruz
  • Sirolimus-eluting Stent
  • High Bleeding Risk
  • Coronary Artery Disease
  • Arteriosclerosis
  • Myocardial Ischemia
  • Vascular Diseases
  • Coronary Intervention
  • Observational Registry
  • Ultra-thin Strut Biodegradable Polymer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All-comer patients affected by silent ischemia, stable angina or acute coronary syndrome (unstable angina and non-STEMI), who qualify for percutaneous coronary intervention (PCI), 400 patients of the population must qualify for HBR criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years old
  2. De novo or re-stenotic significant stenosis in at least one native coronary artery
  3. Patients with silent ischemia, stable angina, unstable angina or non-STEMI eligible for PCI (no limitation of the number of treated lesions and vessels, except higher tercile of Syntax score assessed by the site)
  4. Target lesions suitable for PCI with Drug-eluting Stent (DES) diameter between 2.00 and 4.50 mm
  5. Total lesion length should be from 15 to 120 mm
  6. Patient is willing and capable to sign the written and comply with all requirements of the registry
  7. Planned staged procedures are allowed within 3 months using Supraflex Cruz stent only

Exclusion criteria

Exclusion Criteria:

  1. SYNTAX Score > 32
  2. Hemodynamic instability or cardiogenic shock
  3. Known or to any component of the study stent or the eluting drug, to media contrast, to dual antiplatelet therapy (DAPT) medication required by current practice
  4. Subject is pregnant, nursing or is a woman with
  5. Any co-morbid condition with \< 1 year or that may result in protocol non-compliance
  6. Patients who are participating in another drug or device study, which has not reached its primary endpoint
  7. Patients under judicial protection, tutorship or curatorship
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Supraflex Cruz Sirolimus-eluting Stent

    Device: Supraflex Cruz Sirolimus-eluting Stent

Interventions

  • DeviceSupraflex Cruz Sirolimus-eluting Stent

    Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care

06

What researchers measure

Primary outcomes

  1. Device Oriented Composite Endpoint (DOCE)

    DOCE is a composite of cardiovascular death, myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically-driven target lesion revascularization (TLR)

    Time frame: 12 months

Secondary outcomes

  1. All death, cardiovascular death and non-cardiovascular death

    Time frame: 6 months and 12 months

  2. All myocardial infarction (MI)

    Time frame: 6 months and 12 months

  3. Target vessel MI and MI not clearly attributable to non-target vessel

    Time frame: 6 months and 12 months

  4. Clinically indicated target lesion revascularization (TLR)

    Time frame: 6 months and 12 months

  5. All target lesion revascularization (TLR)

    Clinically and non-clinically indicated target lesion revascularization (TLR)

    Time frame: 6 months and 12 months

  6. All target vessel revascularization (TVR)

    Clinically and non-clinically indicated target vessel revascularization (TVR)

    Time frame: 6 months and 12 months

  7. All revascularization

    Any revascularization, TLR (clinically and non-clinically), TVR (clinically and non-clinically) and non-TVR

    Time frame: 6 months and 12 months

  8. Stent thrombosis (ARC2)

    Time frame: 6 months and 12 months

  9. Device success

    Defined as deployment of the stents without system failure or device-related complication

    Time frame: Up to 1 Day

  10. Lesion success

    Defined as the attainment of \< 50% residual stenosis of the target lesions post-PCI

    Time frame: Up to 1 Day

  11. Procedure success

    Defined as all lesion successfully treated without the occurrence of DOCE during the hospital stay

    Time frame: Up to 7 Days

  12. Major bleeding (BARC 3 to 5) in the HBR population

    Time frame: 6 months and 12 months

07

Study locations

26 sites
  • Centre Hospitalier Haguenau
    Haguenau, 67500, France
  • Hôpital Privé Jacques Cartier
    Massy, 91300, France
  • CHRU de Montpellier
    Montpellier, 34295, France
  • Hôpital Privé Claude Galien
    Quincy-sous-Sénart, 91480, France
  • Clinique Saint Hilaire
    Rouen, 76000, France
  • CHU de Toulouse - Rangueil
    Toulouse, 31059, France
  • Kerckhoff Heart Center
    Bad Nauheim, 61231, Germany
  • Heart and Diabetes Center Nordrhine Westfalia
    Bad Oeynhausen, 32545, Germany
  • Segeberg Kliniken
    Bad Segeberg, 23795, Germany
  • Charité Campus Mitte
    Berlin, 10117, Germany
  • Charité Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Charité Campus Virchow
    Berlin, 13353, Germany
  • St Johannes Hospital
    Dortmund, 44137, Germany
  • Herzzentrum Dresden - Universitätklinikum an der TU Dresden
    Dresden, 01307, Germany
  • Praxisklinik Dresden
    Dresden, Germany
  • HELIOS Klinikum Erfurt
    Erfurt, 99089, Germany
  • University Hospital Erlangen
    Erlangen, 35392, Germany
  • Elizabeth Krankenhaus
    Essen, 45138, Germany
  • UKSH
    Kiel, 24105, Germany
  • Universität Leipzig - Herzzentrum
    Leipzig, 04289, Germany
  • Städtische Kliniken Neuss, Lukaskrankenhaus
    Neuss, 41464, Germany
  • Universitätsklinikum
    Regensburg, 93053, Germany
  • Klinikum Wilhelmshaven
    Wilhelmshaven, 26389, Germany
  • University and Hospital Fribourg
    Fribourg, 1700, Switzerland
  • Kantonsspital St. Gallen
    Saint Gallen, 9000, Switzerland
  • University Hospital Zurich
    Zurich, 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in May 2022, 27 months.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 27 months is close to that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 24, 2019
StartActual
Feb 19, 2020
Primary completionActual
May 31, 2022
CompletionActual
May 31, 2022
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04138238
Lead sponsor
Sahajanand Medical Technologies Limited
Collaborators
European Cardiovascular Research Center
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Feb 19, 2020
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Jul 12, 2023

Study contacts

Prof. Christoph K Naber, PD. Dr. Med.
principal investigator · Klinikum Wilhelmshaven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion